mevastatin has been researched along with Cancer of Prostate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dutta, A; Ukomadu, C | 2 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Beck, JF; Bumbul, B; Sonnemann, J | 1 |
4 other study(ies) available for mevastatin and Cancer of Prostate
| Article | Year |
|---|---|
Inhibition of cdk2 activating phosphorylation by mevastatin.
Topics: Anticholesteremic Agents; CDC2-CDC28 Kinases; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Enzyme Activation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Tumor Cells, Cultured | 2003 |
p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases.
Topics: CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Line; Cell Line, Tumor; Colonic Neoplasms; Cyclin A; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Flow Cytometry; G1 Phase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Lovastatin; Male; Microscopy, Fluorescence; Models, Biological; Phosphorylation; Precipitin Tests; Prostatic Neoplasms; Retinoblastoma Protein; RNA, Messenger; RNA, Small Interfering | 2003 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Lovastatin; Male; Methionine; Mitochondria; Prostatic Neoplasms; Vorinostat; Zoledronic Acid | 2007 |